Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Drug will no longer be available through the CDF for this indication after final guidance is published, but people already taking it will be able to continue.
Please sign in or register for FREE
Sign in to OnMedica
Or sign in via